{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:56:48Z","timestamp":1767056208683,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005969","name":"Universit\u00e0 di Bologna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01773-3","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:43:59Z","timestamp":1764175439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chlormethine gel effectiveness as second-line treatment in mycosis fungoides: a single-centre retrospective study"],"prefix":"10.1007","volume":"16","author":[{"given":"Corrado","family":"Zengarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Guglielmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Vocale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Morsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Mussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12873","author":"C Zengarini","year":"2023","unstructured":"Zengarini C, et al. Nb-UVB and PUVA therapy in treating early stages of Mycosis Fungoides: a single-center cross-sectional study. Photodermatol Photoimmunol Photomed. 2023. https:\/\/doi.org\/10.1111\/phpp.12873.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1773_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1468-3083.2006.01557.x","volume":"20","author":"F Pavlotsky","year":"2006","unstructured":"Pavlotsky F, Barzilai A, Kasem R, Shpiro D, Trau H. UVB in the management of early stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2006;20:565\u201372. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01557.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1773_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/antib13020032","author":"C Zengarini","year":"2024","unstructured":"Zengarini C, et al. A narrative review of the state of the art of CCR4-based therapies in cutaneous T-cell lymphomas: focus on mogamulizumab and future treatments. Antibodies. 2024. https:\/\/doi.org\/10.3390\/antib13020032.","journal-title":"Antibodies"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1111\/jdv.15661","volume":"33","author":"A Pileri","year":"2019","unstructured":"Pileri A, et al. Bexarotene as maintenance treatment after therapies other than skin-directed therapy in advanced-stage mycosis fungoides: a pilot study. J Eur Acad Dermatol Venereol JEADV. 2019;33:e367\u20139. https:\/\/doi.org\/10.1111\/jdv.15661.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1773_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/bjd.21772","volume":"187","author":"G Roccuzzo","year":"2022","unstructured":"Roccuzzo G, et al. Time to next treatment and safety assessment in cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin. Br J Dermatol. 2022;187:1019\u201321. https:\/\/doi.org\/10.1111\/bjd.21772.","journal-title":"Br J Dermatol"},{"key":"1773_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.733770","volume":"11","author":"G Roccuzzo","year":"2021","unstructured":"Roccuzzo G, et al. Immune check point inhibitors in primary cutaneous t-cell lymphomas: biologic rationale, clinical results and future perspectives. Front Oncol. 2021;11: 733770. https:\/\/doi.org\/10.3389\/fonc.2021.733770.","journal-title":"Front Oncol"},{"key":"1773_CR7","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1111\/jdv.19134","volume":"37","author":"M Beylot-Barry","year":"2023","unstructured":"Beylot-Barry M, et al. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol. 2023;37:1777\u201384. https:\/\/doi.org\/10.1111\/jdv.19134.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1773_CR8","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, et al. Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2598\u2013607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1773_CR9","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/jdv.17570","volume":"35","author":"R Ottevanger","year":"2021","unstructured":"Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in patients with Mycosis Fungoides and S\u00e9zary Syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol JEADV. 2021;35:2377\u201387. https:\/\/doi.org\/10.1111\/jdv.17570.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1773_CR10","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s12325-022-02219-w","volume":"39","author":"U Wehkamp","year":"2022","unstructured":"Wehkamp U, Ardig\u00f2 M, Papadavid E, Querfeld C, Nikbakht N. Chlormethine gel for patients with mycosis fungoides cutaneous T cell lymphoma: a review of efficacy and safety in clinical trial and real-world settings. Adv Ther. 2022;39:3979\u20134002. https:\/\/doi.org\/10.1007\/s12325-022-02219-w.","journal-title":"Adv Ther"},{"key":"1773_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19237","author":"E Guenova","year":"2023","unstructured":"Guenova E, Ortiz-Romero PL, Poligone B, Querfeld C. Mechanism of action of chlormethine gel in mycosis fungoides. J Eur Acad Dermatol Venereol JEADV. 2023. https:\/\/doi.org\/10.1111\/jdv.19237.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1773_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther. 2021;11:1085\u2013106. https:\/\/doi.org\/10.1007\/s13555-021-00539-3.","journal-title":"Dermatol Ther"},{"key":"1773_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2023. Eur J Cancer. 2023;195: 113343.","journal-title":"Eur J Cancer"},{"key":"1773_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.23736\/S2784-8671.20.06668-7","volume":"156","author":"S Alberti Violetti","year":"2021","unstructured":"Alberti Violetti S, et al. An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway. Ital J Dermatol Venereol. 2021;156:413\u201321. https:\/\/doi.org\/10.23736\/S2784-8671.20.06668-7.","journal-title":"Ital J Dermatol Venereol"},{"key":"1773_CR15","doi-asserted-by":"publisher","first-page":"1298296","DOI":"10.3389\/fonc.2023.1298296","volume":"13","author":"S Alberti-Violetti","year":"2024","unstructured":"Alberti-Violetti S, et al. Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation. Front Oncol. 2024;13:1298296.","journal-title":"Front Oncol"},{"key":"1773_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22:407\u201314. https:\/\/doi.org\/10.1007\/s40257-021-00591-x.","journal-title":"Am J Clin Dermatol"},{"key":"1773_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40257-022-00687-y","volume":"23","author":"C Querfeld","year":"2022","unstructured":"Querfeld C, et al. Chlormethine gel versus chlormethine ointment for treatment of patients with mycosis fungoides: a post-hoc analysis of clinical trial data. Am J Clin Dermatol. 2022;23:561\u201370. https:\/\/doi.org\/10.1007\/s40257-022-00687-y.","journal-title":"Am J Clin Dermatol"},{"key":"1773_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703\u201314. https:\/\/doi.org\/10.1182\/blood-2018-11-881268.","journal-title":"Blood"},{"key":"1773_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12016-021-08875-0","volume":"61","author":"Y Li","year":"2021","unstructured":"Li Y, Li L. Contact dermatitis: classifications and management. Clin Rev Allergy Immunol. 2021;61:245\u201381. https:\/\/doi.org\/10.1007\/s12016-021-08875-0.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1773_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cod.12432","volume":"73","author":"JD Johansen","year":"2015","unstructured":"Johansen JD, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing\u2014recommendations on best practice. Contact Dermatitis. 2015;73:195\u2013221. https:\/\/doi.org\/10.1111\/cod.12432.","journal-title":"Contact Dermatitis"},{"key":"1773_CR21","first-page":"249","volume":"82","author":"RP Usatine","year":"2010","unstructured":"Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82:249\u201355.","journal-title":"Am Fam Physician"},{"key":"1773_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707\u201313. https:\/\/doi.org\/10.1111\/1523-1747.ep12365600.","journal-title":"J Invest Dermatol"},{"key":"1773_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/DDDT.S137106","volume":"12","author":"K Liner","year":"2018","unstructured":"Liner K, Brown C, McGirt LY. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data. Drug Des Devel Ther. 2018;12:241\u201354. https:\/\/doi.org\/10.2147\/DDDT.S137106.","journal-title":"Drug Des Devel Ther"},{"key":"1773_CR24","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2340\/actadv.v102.1095","volume":"102","author":"M Koumourtzis","year":"2022","unstructured":"Koumourtzis M, Lampadaki K, Dalamaga M, Papadavid E. Chlormethine gel is efficient and safe in mycosis fungoides skin lesions. Acta Derm Venereol. 2022;102:1095. https:\/\/doi.org\/10.2340\/actadv.v102.1095.","journal-title":"Acta Derm Venereol"},{"key":"1773_CR25","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2147\/CMAR.S351420","volume":"14","author":"C Crimp","year":"2022","unstructured":"Crimp C, Gangal A, Tarabadkar ES, Shinohara MM. Mechlorethamine hydrochloride gel in the treatment of mycosis fungoides\u2013type cutaneous T-cell lymphoma (MF-CTCL): a focus on patient selection and special considerations. Cancer Manag Res. 2022;14:3271\u20139. https:\/\/doi.org\/10.2147\/CMAR.S351420.","journal-title":"Cancer Manag Res"},{"key":"1773_CR26","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.11.03","author":"M-L Lovgren","year":"2019","unstructured":"Lovgren M-L, Scarisbrick JJ. Update on skin directed therapies in mycosis fungoides. Chin Clin Oncol. 2019. https:\/\/doi.org\/10.21037\/cco.2018.11.03.","journal-title":"Chin Clin Oncol"},{"key":"1773_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/aje\/kwq426","volume":"173","author":"M Doi","year":"2011","unstructured":"Doi M, et al. Effect of mustard gas exposure on incidence of lung cancer: a longitudinal study. Am J Epidemiol. 2011;173:659\u201366. https:\/\/doi.org\/10.1093\/aje\/kwq426.","journal-title":"Am J Epidemiol"},{"key":"1773_CR28","unstructured":"N. T. Program. Nitrogen mustard hydrochloride. In: 15th report on carcinogens, National toxicology program; 2021. Consultato: 17 giugno 2024. Disponibile su: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK590793\/"},{"key":"1773_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s13555-022-00871-2","volume":"13","author":"LM Fahmy","year":"2022","unstructured":"Fahmy LM, Kwinta BD, Schreidah CM, Ferris LK, Geskin LJ. Topical mechlorethamine for the treatment of psoriasis: a report of two cases and literature review. Dermatol Ther. 2022;13:617\u201327. https:\/\/doi.org\/10.1007\/s13555-022-00871-2.","journal-title":"Dermatol Ther"},{"key":"1773_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.12620","volume":"170","author":"LM Lindahl","year":"2014","unstructured":"Lindahl LM, Fenger-Gr\u00f8n M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2014;170:699\u2013704. https:\/\/doi.org\/10.1111\/bjd.12620.","journal-title":"Br J Dermatol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01773-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:52:05Z","timestamp":1767055925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01773-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave informed consent to participate in the study. Study approved by the Ethical committee under n\u00b0 Clin.Isto. Tp.19, Bologna local ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patients in this manuscript have given written informed consent to the publication of their case details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2301"}}